Inflated Charges Lead to $30 Million False Claims Settlement
This case originated as a qui tam, or whistleblower, case under provisions of the False Claims Act that permit private citizens with knowledge of fraud against the government to bring an action on behalf of the United States and to share in the recovery. In this qui tam matter, the relator who brought the case will receive over $5 million.
Government lawyers reiterated that pharmaceutical companies should be aware that the government is scrutinizing records “to detect all forms of health care fraud.” In its release, the government stated its hope that “vigorous civil and criminal enforcement will deter companies from defrauding taxpayers in the future.”